logo-loader

Full interview: Lexaria Bio Science files patent for technology to treat infection disease including Corona

Published: 16:24 21 Apr 2020 EDT

Lexaria Bioscience (CSE: LXX-OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to discuss the company has filed a patent for their DehydraTech technology for the delivery of antiviral drugs.

Bunka telling Proactive this technology would potentially be used to improve treatment options for viral infectious diseases including COVID-19, MERS, SARS, influenza, herpes, hepatitis and AIDS.

Lexaria Bioscience Revolutionizes Drug Delivery with DehydraTECH for GLP-1 drug

Lexaria BioScience CEO Chris Bunka joined Steve Darling from Proactive to share significant updates regarding its focus on DehydraTECH, a patented drug delivery formulation and processing platform technology aimed at improving the oral delivery of active pharmaceutical ingredients. Lexaria...

1 week, 3 days ago